The upcoming report from Chipotle Mexican Grill (CMG) is expected to reveal quarterly earnings of $0.28 per share, indicating an increase of 3.7% compared to the year-ago period. Analysts forecast revenues of $2.94 billion, representing an increase of 8.7% year over year.Over the last 30 days, there has been a downward revision of 2.5% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over ...

The upcoming report from Newmont Corporation (NEM) is expected to reveal quarterly earnings of $0.84 per share, indicating an increase of 52.7% compared to the year-ago period. Analysts forecast revenues of $4.54 billion, representing an increase of 13% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 14.5% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to ...

Core Viewpoint - Analysts project that Thermo Fisher Scientific (TMO) will report quarterly earnings of $5.10 per share, reflecting a 0.2% decline year over year, with revenues expected to reach $10.25 billion, down 0.9% from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating a reassessment by covering analysts [1][2]. - Revisions to earnings estimates are crucial for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [2]. Revenue Projections - Analysts forecast 'Revenues- Laboratory Products and Biopharma Services' to reach $5.61 billion, indicating a decline of 2.1% from the prior-year quarter [4]. - 'Revenues- Specialty Diagnostics' is expected to be $1.10 billion, reflecting a decrease of 0.5% year over year [4]. - 'Revenues- Life Sciences Solutions' is projected at $2.28 billion, showing a year-over-year change of -0.3% [4]. Geographic Revenue Estimates - 'Revenues- Analytical Instruments' is expected to reach $1.73 billion, suggesting a year-over-year increase of 2.5% [5]. - 'Geographic Revenues- Customer Location- North America' is projected at $5.43 billion, indicating a decline of 1.7% year over year [5]. - 'Geographic Revenues- Customer Location- Asia-Pacific' is estimated at $1.88 billion, reflecting a growth of 0.8% [5]. - 'Geographic Revenues- Customer Location- Other regions' is expected to reach $368.42 million, indicating a year-over-year increase of 6.5% [6]. - 'Geographic Revenues- Customer Location- Europe' is projected at $2.60 billion, reflecting a decrease of 0.7% from the year-ago quarter [6]. Stock Performance - Shares of Thermo Fisher have shown a return of -15.7% over the past month, compared to a -6.3% change in the Zacks S&P 500 composite [6].

One stock that might be an intriguing choice for investors right now is Fresenius Medical Care AG (FMS) . This is because this security in the Medical - Instruments space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in ...

Company Overview - Unifirst Corporation (UNF) is currently positioned as an intriguing investment choice due to solid earnings estimate revision activity and a favorable Zacks Industry Rank [1][5] - The company has seen a rise in earnings estimates, indicating a more bullish outlook from analysts for both short and long-term prospects [3][4] Industry Context - The Industrial Products space, where Unifirst operates, has a Zacks Industry Rank of 12 out of 247 industries, suggesting strong overall positioning compared to other segments [2] - A broad trend in the industry is likely benefiting multiple securities, indicating a rising tide effect that could lift all boats within this sector [2] Earnings Estimates - Over the past month, current quarter earnings estimates for Unifirst have increased from $2.07 per share to $2.14 per share, while current year estimates have risen from $7.63 per share to $7.94 per share [4] - These revisions have contributed to Unifirst earning a Zacks Rank of 2 (Buy), highlighting its solid market position [4]

Company Insights - Velocity Financial, Inc. (VEL) is currently experiencing solid earnings estimate revisions, indicating a positive outlook from analysts [3][4] - Over the past 60 days, current quarter earnings estimates have increased from $0.47 per share to $0.52 per share, and current year estimates have risen from $1.97 per share to $2.19 per share [4] - Velocity Financial has achieved a Zacks Rank 1 (Strong Buy), highlighting its strong position in the market [4] Industry Overview - The Finance sector, where Velocity Financial operates, holds a Zacks Industry Rank of 38 out of 247 industries, suggesting it is well-positioned compared to other segments [2] - The positive trends in the Finance space indicate that a rising tide may benefit multiple companies within the industry [2]

Company Overview - Intercontinental Exchange, Inc. (ICE) is currently positioned as an intriguing investment choice due to solid earnings estimate revisions and a favorable industry ranking [1][5]. - The company has experienced positive earnings estimate revisions over the past month, indicating increased analyst optimism regarding its short and long-term prospects [3]. Industry Context - The Securities and Exchanges industry, where ICE operates, holds a Zacks Industry Rank of 9 out of more than 250 industries, suggesting a strong position relative to other sectors [2]. - The overall positive trends in the Securities and Exchanges space are likely benefiting multiple companies within the industry, indicating a rising tide effect [2]. Earnings Estimates - Current quarter earnings estimates for ICE have increased from $1.66 per share to $1.70 per share, while current year estimates have risen from $6.73 per share to $6.83 per share [4]. - These revisions have contributed to ICE earning a Zacks Rank 2 (Buy), highlighting its solid market position [4].

Core Viewpoint - Analysts forecast Elevance Health (ELV) to report quarterly earnings of $11.09 per share, reflecting a year-over-year increase of 4.2%, with revenues expected to reach $45.93 billion, an increase of 8.7% compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 1.5% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate trends and short-term stock performance [3]. Revenue Projections - Analysts expect 'Revenues- Premiums' to be $38.66 billion, indicating a year-over-year change of +8.3% [4]. - 'Revenues- Service fees' are projected to reach $2.13 billion, reflecting a change of +2.6% from the previous year [5]. - 'Revenues- Net investment income' is expected to be $461.32 million, showing a year-over-year change of -0.8% [5]. - 'Revenues- Product revenue' is anticipated to reach $5.11 billion, indicating a change of +13.6% from the prior year [5]. Membership Metrics - Total Medical Membership is forecasted to be 46.24 million, consistent with the same quarter last year [6]. - 'Medical Membership - Medicare - Medicare Advantage' is expected to reach 2.21 million, up from 2.02 million in the same quarter last year [6]. - 'Medical Membership - Medicaid' is estimated at 8.89 million, down from 9.33 million in the previous year [7]. - 'Medical Membership - Federal Employees Health Benefits' is projected to remain at 1.66 million, unchanged from the year-ago figure [7]. - The consensus for 'Medical Membership - Total Medicare' stands at 3.08 million, up from 2.91 million last year [8]. - 'Medical Membership - Commercial Risk-Based - Individual' is expected to reach 1.42 million, compared to 1.25 million in the same quarter last year [8]. Expense Ratios - The 'Benefit Expense Ratio' is projected to be 87.3%, up from 85.6% in the same quarter last year [9]. - 'Medical Membership - Commercial Fee-Based' is expected to be 27.44 million, slightly down from 27.45 million in the previous year [9]. Stock Performance - Elevance Health shares have increased by +0.4% over the past month, contrasting with the Zacks S&P 500 composite's decline of -4.2% [9].

Core Insights - Wall Street analysts expect Danaher (DHR) to report quarterly earnings of $1.62 per share, reflecting a year-over-year decline of 15.6% [1] - Revenues are anticipated to be $5.56 billion, down 4.2% from the same quarter last year [1] - The consensus EPS estimate has been revised 0.1% lower over the last 30 days, indicating a reevaluation of initial estimates by analysts [1][2] Revenue Estimates - The consensus estimate for 'Total sales- Diagnostics' is $2.34 billion, indicating a decline of 7.2% from the prior-year quarter [4] - 'Total sales- Life Sciences' is expected to reach $1.64 billion, reflecting a decrease of 6% year-over-year [4] - 'Total sales- Biotechnology' is projected at $1.59 billion, suggesting a year-over-year increase of 4% [4] Operating Profit Estimates - Analysts estimate 'Operating profit- Life Sciences' to be $199.97 million, down from $235 million reported in the same quarter last year [5] - 'Operating profit- Biotechnology' is expected to reach $398.00 million, compared to $325 million in the same quarter of the previous year [5] - The estimated 'Operating profit- Diagnostics' stands at $585.46 million, a decrease from $830 million a year ago [6] Stock Performance - Over the past month, Danaher's shares have returned -10.7%, while the Zacks S&P 500 composite has changed by -4.2% [6] - Currently, Danaher carries a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [6]

Core Viewpoint - Analysts forecast that American Express (AXP) will report quarterly earnings of $3.46 per share, reflecting a year-over-year increase of 3.9%, with anticipated revenues of $17 billion, marking a 7.6% increase compared to the previous year [1] Earnings Estimates - Over the last 30 days, there has been a downward revision of 0.2% in the consensus EPS estimate for the quarter, indicating a collective reconsideration by analysts [2] - Revisions to earnings projections are crucial for predicting investor behavior, as empirical studies show a strong correlation between earnings estimate trends and short-term stock performance [3] Key Metrics Forecast - Analysts estimate 'Commercial Services - Card Member Loans - Total loans' at $31.20 billion, up from $27.6 billion year-over-year [5] - The forecast for 'International Card Services - Card Member loans - consumer and small business - Average loans' is $17.96 billion, compared to $16.4 billion last year [6] - 'U.S. Consumer Services - Card Member loans - Total loans' is expected to reach $89.44 billion, an increase from $82.3 billion in the same quarter last year [7] - The average prediction for 'Average Card Member loans' is $137.87 billion, up from $124.7 billion year-over-year [8] - The consensus estimate for 'Total non-interest revenues' stands at $12.83 billion, compared to $12.03 billion in the same quarter last year [9] - Analysts project 'Net Interest Income' to reach $4.11 billion, an increase from $3.77 billion last year [10] Stock Performance - Shares of American Express have decreased by 5.5% over the past month, compared to a 3.6% decline in the Zacks S&P 500 composite, with a Zacks Rank of 3 (Hold) indicating expected performance in line with the overall market [11]